Opiorphin

Overview

Opiorphin is a pentapeptide (Gln-Arg-Phe-Ser-Arg, QRFSR) isolated from human saliva in 2006 by Catherine Rougeot and colleagues at the Institut Pasteur. It represents the human counterpart of sialorphin, a related pentapeptide (QHNPR) that had been isolated earlier from rat submandibular gland by the same research program. The "-orphin" suffix reflects the peptide's opioid-like analgesic activity, though the mechanism of action is indirect.

What makes opiorphin distinctive is that it is not itself an opioid receptor agonist. Instead, it functions as a dual inhibitor of the two principal enkephalin-degrading enzymes: neutral endopeptidase (NEP/neprilysin) and aminopeptidase N (APN/CD13). By blocking the breakdown of endogenous enkephalins, opiorphin prolongs their duration of action at delta- and mu-opioid receptors, amplifying the analgesic tone of the endogenous opioid system.

This "enkephalinase inhibitor" mechanism is pharmacologically distinct from direct opioid agonism and has implications for analgesic tolerance and dependence profiles. By potentiating rather than mimicking endogenous opioid signaling, enkephalinase inhibitors like opiorphin may produce analgesia with reduced likelihood of the respiratory depression, tolerance, and dependence associated with direct opioid agonists — though this theoretical advantage has required extensive pharmacological validation.

Opiorphin's discovery was part of a broader research trajectory exploring salivary glands as a source of novel bioactive peptides, building on earlier work with sialorphin and related peptides. Human opiorphin is produced in sublingual glands and appears in saliva at variable concentrations; it has been detected in tears and other body fluids as well. The physiological role of salivary opiorphin is still under investigation — proposed roles include modulation of oral pain, stress-responsive local analgesia, and regulation of mucosal homeostasis.

Structure/Sequence

Human Opiorphin: Gln-Arg-Phe-Ser-Arg (QRFSR)

• Length: 5 amino acids (pentapeptide)
• Molecular weight: ~692 g/mol
• Source: Human saliva, sublingual gland
• Free N- and C-termini: Not amidated
• Basic character: Two arginines, one glutamine
• Parent protein: Derived from proline-rich protein BPLP (basic proline-rich lipoprotein)

Comparison with Sialorphin (Rat)

• Sialorphin: QHNPR (5 aa)
• Opiorphin: QRFSR (5 aa)
• Both pentapeptides with similar charge profiles
• Both inhibit NEP and APN
• Species counterparts from submandibular/sublingual glands

Structural Features

• Rigid polyproline backbone influence: Presence of imine residues constrains conformation
• Positive charge cluster (Arg2, Arg5): Important for enzyme active-site interactions
• Phenylalanine (Phe3): Hydrophobic contact with enzyme substrate groove

Related Fragments

Various short analogs have been synthesized to probe structure-activity relationships and optimize half-life:

• N-methylated analogs for protease resistance
• D-amino acid substitutions
• Cyclic analogs

Mechanism of Action

Enzyme Inhibition Profile

Opiorphin inhibits two enkephalin-degrading enzymes:

Neprilysin (NEP, CD10, Enkephalinase):

• Membrane-bound zinc metallopeptidase
• Cleaves enkephalins at Gly-Phe bond
• Inactivates many peptides including enkephalins, substance P, atrial natriuretic peptide, bradykinin
• Opiorphin Ki: low micromolar range

Aminopeptidase N (APN, CD13):

• Membrane-bound zinc aminopeptidase
• Cleaves N-terminal Tyr from enkephalins and related peptides
• Opiorphin Ki: low micromolar range

Indirect Opioid Potentiation

By blocking enkephalin degradation, opiorphin:

• Increases local enkephalin concentrations at sites of release
• Prolongs enkephalin action at δ- and μ-opioid receptors
• Analgesic effects in rodent models blocked by naloxone
• Effects also blocked by δ and μ selective antagonists

Analgesia Properties

• Systemic or local administration produces analgesia in multiple rodent pain models
• Anti-hyperalgesic in inflammatory pain
• Active in neuropathic pain models
• Naloxone-reversible, confirming opioid-mediated mechanism

Antidepressant-Like Effects

• Opiorphin shows antidepressant-like activity in forced swim and tail suspension tests
• Consistent with enkephalin involvement in mood regulation
• Delta-opioid receptor signaling implicated

Potential Tolerance Profile

• Reduced tolerance development compared to direct opioid agonists in some studies
• Lesser reinforcement in self-administration paradigms
• Reduced respiratory depression potential theorized but requires validation

Peripheral vs Central Effects

• Peripheral opiorphin potentiates peripheral enkephalin signaling (relevant for oral and GI pain)
• Central administration requires BBB penetration, which is limited for native peptide
• Stabilized analogs and lipophilic prodrugs explored for CNS delivery

Research Summary

Common Discussion Topics

1. Enkephalinase inhibitor strategy — Opiorphin illustrates a pharmacological strategy distinct from direct opioid agonism: potentiate the endogenous opioid system by blocking its degradation. This indirect approach may yield analgesia with reduced tolerance and dependence, though this theoretical advantage requires extensive validation. Similar strategies underlie development of combined NEP-APN inhibitors (e.g., RB101) as research tools.

2. Salivary gland as peptide source — The discovery of both sialorphin and opiorphin from salivary glands highlighted these tissues as underappreciated sources of bioactive peptides. Local peptide signaling in oral mucosa may contribute to homeostasis and stress responses.

3. Indirect vs direct opioid pharmacology — Comparing direct MOR agonists (morphine, endomorphin-1) with enkephalinase inhibitors (opiorphin) provides insight into the consequences of sustained vs pulsatile opioid receptor activation. The indirect approach may preserve physiological signaling patterns that are disrupted by direct agonists.

4. Comparison to kyotorphin — Both opiorphin and kyotorphin produce analgesia through indirect mechanisms involving endogenous opioid peptides — opiorphin by blocking degradation, kyotorphin by promoting release. Together they illustrate multiple indirect routes to opioid analgesia.

5. Salivary biomarker potential — Opiorphin concentrations in saliva vary with physiological state. Investigation of opiorphin as a salivary stress biomarker or as a marker of oral pain states is an active research area, though standardization of measurement remains a challenge.

Related Compounds

• Enkephalins — the endogenous peptides whose activity opiorphin potentiates
• Endomorphin-1 — direct MOR-selective endogenous opioid
• Kyotorphin — another indirect endogenous opioid mechanism
• Beta-endorphin — POMC-derived endogenous opioid